The role and utility of faecal markers in inflammatory bowel disease

Therapeutic Advances in Gastroenterology

Volumn 8, Issue 1, 2015, Pages 23-36

  Lehmann, Frank S ^a   Burri, Emanuel ^a   Beglinger, Christoph ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

calprotectin; Crohns disease; inflammation; inflammatory bowel disease; lactoferrin; ulcerative colitis

Indexed keywords

ALPHA 1 ANTITRYPSIN; BETA DEFENSIN 2; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALGRANULIN; ELASTASE; GELATINASE A; GELATINASE B; HEMOGLOBIN; INTERSTITIAL COLLAGENASE; LACTOFERRIN; LYSOZYME; MYELOPEROXIDASE; NEOPTERIN; POLYMORPHONUCLEAR ELASTASE; PROTEIN; PROTEIN X; PYRUVATE KINASE; S100A12 PROTEIN; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

COLONOSCOPY; CROHN DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FECES; HEALING; HUMAN; INFLAMMATORY BOWEL DISEASE; INTERMETHOD COMPARISON; IRRITABLE COLON; LEUKOCYTE; PATIENT MONITORING; POSTOPERATIVE PERIOD; PREDICTIVE VALUE; PROCTOCOLECTOMY; RECURRENT DISEASE; REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; ULCERATIVE COLITIS;

EID: 84919475176     PISSN: 1756283X     EISSN: 17562848     Source Type: Journal    
DOI: 10.1177/1756283X14553384     Document Type: Review

References (110)

1. Annaházi A. Molnár T. Farkas K. Rosztóczy A. Izbéki F. Gecse K. et al. (2013) Fecal MMP-9: a new noninvasive differential diagnostic and activity marker in ulcerative colitis. Inflamm Bowel Dis 19: 316–320.
2. Baugh M. Perry M. Hollander A. Davies D. Cross S. Lobo A. et al. (1999) Matrix metalloproteinase levels are elevated in inflammatory bowel disease. Gastroenterology 117: 814–822.
3. Bernell O. Lapidus A. Hellers G. (2000) Risk factors for surgery and recurrence in 907 patients with primary ileocaecal Crohn's disease. Br J Surg 87: 1697–1701.
4. Bjerke K. Halstensen T. Jahnsen F. Pulford K. Brandtzaeg P. (1993) Distribution of macrophages and granulocytes expressing L1Protein (calprotectin) in human Peyer's patches compared with normal ileal lamina propria and mesenteric lymph nodes. Gut 34: 1357–1363.
5. Bremner A. Roked S. Robinson R. Phillips I. Beattie M. (2005) Faecal calprotectin in children with chronic gastrointestinal symptoms. Acta Paediatr 94: 1855–1858.
6. Buderus S. Boone J. Lyerly D. Lentze M. (2004) Fecal lactoferrin: a new parameter to monitor infliximab therapy. Dig Dis Sci 49: 1036–1039.
7. Bunn S. Bisset W. Main M. Golden B. (2001) Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr 32: 171–177.
8. Bunn S. Bisset W. Main M. Gray E. Olson S. Golden B. (2001) Fecal calprotectin: validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr 33: 14–22.
9. Burri E. Beglinger C. (2012) Faecal calprotectin – a useful tool in the management of inflammatory bowel disease. Swiss Med Wkly 142: 1–12.
10. Burri E. Manz M. Rothen C. Rossi L. Beglinger C. Lehmann F. (2013) Monoclonal antibody testing for fecal calprotectin is superior to polyclonal testing of fecal calprotectin and lactoferrin to identify organic intestinal disease in patients with abdominal discomfort. Clin Chim Acta 416: 41–47
11. Canani R. Terrin G. Rapacciuolo L. Miele E. Siani M. Puzone C. et al. (2008) Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig Liver Dis 40: 547–553.
12. Carroccio A. Iacono G. Cottone M. Di Prima L. Cartabellotta F. Cavataio F. et al. (2003) Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children. Clin Chem 49: 861–867
13. Casellas F. Borruel N. Antolín M. Varela E. Torrejón A. Armadans L. et al. (2007) Fecal excretion of deoxyribonucleic acid in long-term follow-up of patients with inactive ulcerative colitis. Inflamm Bowel Dis 13: 386–390.
14. Chung-Faye G. Hayee B. Maestranzi S. Donaldson N. Forgacs I. Sherwood R. (2007) Fecal M2-pyruvate kinase (M2-PK): a novel marker of intestinal inflammation. Inflamm Bowel Dis 13: 1374–1378
15. Colombel J. Sandborn W. Reinisch W. Mantzaris G. Kornbluth A. Rachmilewitz D. et al. (2010) Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 362: 1383–1395.
16. Costa F. Mumolo M. Bellini M. Romano M. Ceccarelli L. Arpe P. et al. (2003) Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis 35: 642–647.
17. Costa F. Mumolo M. Ceccarelli L. Bellini M. Romano M. Sterpi C. et al. (2005) Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut 54: 364–368.
18. Czub E. Herzig K. Szaflarska-Popawska A. Kiehne K. Socha P. Woś H. et al. (2007) Fecal pyruvate kinase: a potential new marker for intestinal inflammation in children with inflammatory bowel disease. Scand J Gastroenterol 42: 1147–1150.
19. Dai J. Liu W. Zhao Y. Hu Y. Ge Z. (2007) Relationship between fecal lactoferrin and inflammatory bowel disease. Scand J Gastroenterol 42: 1440–1444.
20. de Jong N. Leach S. Day A. (2006) Fecal S100A12: a novel noninvasive marker in children with Crohn's disease. Inflamm Bowel Dis. 12: 566–572.
21. de Vos M. Dewit O. D'Haens G. Baert F. Fontaine F. Vermeire S. et al. (2012) Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naïve patients with ulcerative colitis. J Crohns Colitis 6: 557–562.
22. D'Haens G. Ferrante M. Vermeire S. Baert F. Noman M. Moortgat L. et al. (2012) Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 18: 2218–2224.
23. Diamanti A. Colistro F. Basso M. Papadato B. Francalanci P. Bracci F. et al. (2008) Clinical role of calprotectin assay in determining histological relapses in children affected by inflammatory bowel diseases. Inflamm Bowel Dis 14: 1229–1235.
24. Diamanti A. Panetta F. Basso M. Forgione A. Colistro F. Bracci F. et al. (2010) Diagnostic work-up of inflammatory bowel disease in children: the role of calprotectin assay. Inflamm Bowel Dis 16: 1926–1930.
25. D'Incà R. Dal Pont E. Di Leo V. Benazzato L. Martinato M. Lamboglia F. et al. (2008) Can calprotectin predict relapse risk in inflammatory bowel disease? Am J Gastroenterol 103: 2007–2014.
26. D'Incà R. Dal Pont E. Di Leo V. Ferronato A. Fries W. Vettorato M. et al. (2007) Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Colorectal Dis 22: 429–437.
27. Dolwani S. Metzner M. Wassell J. Yong A. Hawthorne A. (2004) Diagnostic accuracy of faecal calprotectin estimation in prediction of abnormal small bowel radiology. Aliment Pharmacol Ther 20: 615–621.
28. Fagerberg U. Lööf L. Lindholm J. Hansson L. Finkel Y. (2007) Fecal calprotectin: a quantitative marker of colonic inflammation in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 45: 414–420.
29. Fagerberg U. Lööf L. Myrdal U. Hansson L. Finkel Y. (2005) Colorectal inflammation is well predicted by fecal calprotectin in children with gastrointestinal symptoms. J Pediatr Gastroenterol Nutr 40: 450–455.
30. Fagerhol M. Dale I. Andersson T. (1980) A radioimmunoassay for a granulocyte protein as a marker in studies on the turnover of such cells. Bull Eur Physiopathol Respir 16(Suppl.): 273–282.
31. Foell D. Wittkowski H. Ren Z. Turton J. Pang G. Daebritz J. et al. (2008) Phagocyte-specific S 100 proteins are released from affected mucosa and promote immune responses during inflammatory bowel disease. J Pathol 216: 183–192
32. Foell D. Wittkowski H. Roth J. (2009) Monitoring disease activity by stool analyses: from occult blood to molecular markers of intestinal inflammation and damage. Gut 58: 859–868
33. García-Sánchez V. Iglesias-Flores E. González R. Gisbert J. Gallardo-Valverde J. González-Galilea A. et al. (2010) Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis? J Crohns Colitis 4: 144–152.
34. Gaya D. Lyon T. Duncan A. Neilly J. Han S. Howell J. et al. (2005) Faecal calprotectin in the assessment of Crohn's disease activity. QJM 98: 435–441.
35. Gisbert J. McNicholl A. (2009) Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Dig Liver Dis 41: 56–66.
36. Gisbert J. McNicholl A. Gomollon F. (2009) Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease. Inflamm Bowel Dis 15: 1746–1754.
37. Henderson P. Anderson N. Wilson D. (2014) The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 109: 637–645.
38. Henderson P. Casey A. Lawrence S. Kennedy N. Kingstone K. Rogers P. et al. (2012) The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease. Am J Gastroenterol 107: 941–949.
39. Ho G. Lee H. Brydon G. Ting T. Hare N. Drummond H. et al. (2009) Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis. Am J Gastroenterol 104: 673–678.
40. Husebye E. Ton H. Johne B. (2001). Biological variability of fecal calprotectin in patients referred for colonoscopy without colonic inflammation or neoplasm1. Am J Gastroenterol 96: 2683–2687.
41. Jensen M. Kjeldsen J. Nathan T. (2011) Fecal calprotectin is equally sensitive in Crohn's disease affecting the small bowel and colon. Scand J Gastroenterol 46: 694–700.
42. Johnson M. Maestranzi S. Duffy A. Dewar D. Forbes A. Bjarnason I. et al. (2008) Faecal calprotectin: a noninvasive diagnostic tool and marker of severity in pouchitis. Eur J Gastroenterol Hepatol 20: 174–179.
43. Jones J. Loftus E. Jr Panaccione R. Chen L. Peterson S. McConnell J. et al. (2008) Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol 6: 1218–1224.
44. Kaiser T. Langhorst J. Wittkowski H. Becker K. Friedrich A. Rueffer A. et al. (2007) Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. Gut 56: 1706–1713.
45. Kane S. Sandborn W. Rufo P. Zholudev A. Boone J. Lyerly D. et al. (2003) Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol 98: 1309–1314.
46. Kok L. Elias S. Witteman B. Goedhard J. Muris J. Moons K. et al. (2012) Diagnostic accuracy of point-of-care fecal calprotectin and immunochemical occult blood tests for diagnosis of organic bowel disease in primary care: the Cost-Effectiveness of a Decision Rule for Abdominal Complaints in Primary Care (CEDAR) study. Clin Chem 58: 989–998.
47. Kolho K. Raivio T. Lindahl H. Savilahti E. (2006) Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel disease. Scand J Gastroenterol 41: 720–725.
48. Kolho K. Sipponen T. (2014) The long-term outcome of anti-tumor necrosis factor-α therapy related to fecal calprotectin values during induction therapy in pediatric inflammatory bowel disease. Scand J Gastroenterol 49: 434–441.
49. Kolho K. Sipponen T. Valtonen E. Savilahti E. (2014) Fecal calprotectin, MMP-9, and human beta-defensin-2 levels in pediatric inflammatory bowel disease. Int J Colorectal Dis 29: 43–50.
50. Kolho K. Turner D. Veereman-Wauters G. Sladek M. de Ridder L. Shaoul R. et al. (2012) Rapid test for fecal calprotectin levels in children with Crohn disease. J Pediatr Gastroenterol Nutr 55: 436–439.
51. Konikoff M. Denson L. (2006) Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis 12: 524–534.
52. Lamb C. Mohiuddin M. Gicquel J. Neely D. Bergin F. Hanson J. et al. (2009) Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn's disease. Br J Surg 96: 663–674.
53. Langhorst J. Elsenbruch S. Koelzer J. Rueffer A. Michalsen A. Dobos G. (2008) Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol 103: 162–169.
54. Langhorst J. Elsenbruch S. Mueller T. Rueffer A. Spahn G. Michalsen A. et al. (2005) Comparison of 4 neutrophil-derived proteins in feces as indicators of disease activity in ulcerative colitis. Inflamm Bowel Dis 11: 1085–1091.
55. Lasson A. Stotzer P. Ohman L. Isaksson S. Sapnara M. Strid H. (2014) The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis. J Crohns Colitis 5 July 2014 [Epub ahead of print].
56. Lehmann F. Trapani F. Fueglistaler I. Terracciano L. von Flüe M. Cathomas G. et al. (2014) Clinical and histopathological correlations of fecal calprotectin release in colorectal carcinoma. World J Gastroenterol 20: 4994–4999.
57. Lim M. Gonsalves S. Thekkinkattil D. Seedat S. Finan P. Sagar P. et al. (2008) The assessment of a rapid noninvasive immunochromatographic assay test for fecal lactoferrin in patients with suspected inflammation of the ileal pouch. Dis Colon Rectum 51: 96–99.
58. Lobatón T. López-García A. Rodríguez-Moranta F. Ruiz A. Rodríguez L. Guardiola J. (2013) A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease. J Crohns Colitis 7: e641–e651.
59. Louis E. Mary J. Vernier-Massouille G. Grimaud J. Bouhnik Y. Laharie D. et al. (2012) Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 142: 63–70.
60. Manolakis A. Kapsoritakis A. Georgoulias P. Tzavara C. Valotassiou V. Kapsoritaki A. et al. (2010) Moderate performance of serum S100A12, in distinguishing inflammatory bowel disease from irritable bowel syndrome. BMC Gastroenterol 10: 118.
61. Manz M. Burri E. Rothen C. Tchanguizi N. Niederberger C. Rossi L. et al. (2012) Value of fecal calprotectin in the evaluation of patients with abdominal discomfort: an observational study. BMC Gastroenterol 12: 5.
62. Mao R. Xiao Y. Gao X. Chen B. He Y. Yang L. et al. (2012) Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies. Inflamm Bowel Dis 18: 1894–1899.
63. Masoodi I. Kochhar R. Dutta U. Vaishnavi C. Prasad K. Vaiphei K. et al. (2009) Fecal lactoferrin, myeloperoxidase and serum C-reactive are effective biomarkers in the assessment of disease activity and severity in patients with idiopathic ulcerative colitis. J Gastroenterol Hepatol 24: 1768–1774.
64. Mooiweer E. Fidder H. Siersema P. Laheij R. Oldenburg B. (2014) Fecal hemoglobin and calprotectin are equally effective in identifying patients with inflammatory bowel disease with active endoscopic inflammation. Inflamm Bowel Dis 20: 307–314.
65. Molander P. Af Björkesten C. Mustonen H. Haapamäki J. Vauhkonen M. Kolho K. et al. (2012) Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents. Inflamm Bowel Dis 18: 2011–2017.
66. Moum B. Jahnsen J. Bernklev T. (2010) Fecal calprotectin variability in Crohn's disease. Inflamm Bowel Dis 16: 1091–1092.
67. Naismith G. Smith L. Barry S. Munro J. Laird S. Rankin K. et al. (2013) A prospective single-centre evaluation of the intra-individual variability of faecal calprotectin in quiescent Crohn's disease. Aliment Pharmacol Ther 37: 613–621.
68. Nancey S. Boschetti G. Moussata D. Cotte E. Peyras J. Cuerq C. et al. (2013) Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases. Inflamm Bowel Dis 19: 1043–1052.
69. Orlando A. Modesto I. Castiglione F. Scala L. Scimeca D. Rispo A. et al. (2006) The role of calprotectin in predicting endoscopic post-surgical recurrence in asymptomatic Crohn's disease: a comparison with ultrasound. Eur Rev Med Pharmacol Sci 10: 17–22.
70. Pakarinen M. Koivusalo A. Natunen J. Ashorn M. Karikoski R. Aitola P. et al. (2010) Fecal calprotectin mirrors inflammation of the distal ileum and bowel function after restorative proctocolectomy for pediatric-onset ulcerative colitis. Inflamm Bowel Dis 16: 482–486.
71. Papay P. Ignjatovic A. Karmiris K. Amarante H. Milheller P. Feagan B. et al. (2013) Optimising monitoring in the management of Crohn's disease: a physician's perspective. J Crohns Colitis 7: 653–669.
72. Parsi M. Shen B. Achkar J. Remzi F. Goldblum J. Boone J. et al. (2004) Fecal lactoferrin for diagnosis of symptomatic patients with ileal pouch-anal anastomosis. Gastroenterology 126: 1280–1286.
73. Peyrin-Biroulet L. Ferrante M. Magro F. Campbell S. Franchimont D. Fidder H. et al.; Scientific Committee of the European Crohn's and Colitis Organization (2011) Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease. J Crohns Colitis 5: 477–483.
74. Pineton d.e. Chambrun G. Peyrin-Biroulet L. Lémann M. Colombel J. (2010) Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol 7: 15–29.
75. Ricanek P. Brackmann S. Perminow G. Lyckander L. Sponheim J. Holme O. et al. (2011) Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers. Scand J Gastroenterol 46: 1081–1091.
76. Roseth A. Aadland E. Grzyb K. (2004) Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol 39: 1017–1020.
77. Roseth A. Aadland E. Jahnsen J. Raknerud N. (1997) Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion 58: 176–180.
78. Roseth A. Fagerhol M. Aadland E. Schjonsby H. (1992) Assessment of the neutrophil dominating protein calprotectin in faeces. A methodological study. Scand J Gastroenterol 27: 793–798.
79. Roseth A. Schmidt P. Fagerhol M. (1999) Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol 34: 50–54.
80. Rutgeerts P. Geboes K. Vantrappen G. Beyls J. Kerremans R. Hiele M. (1990) Predictability of the postoperative course of Crohn's disease. Gastroenterology 99: 956–963.
81. Scarpa M. D'Incà R. Basso D. Ruffolo C. Polese L. Bertin E. et al. (2007) Fecal lactoferrin and calprotectin after ileocolonic resection for Crohn's disease. Dis Colon Rectum 50: 861–869.
82. Schoepfer A. Beglinger C. Straumann A. Safroneeva E. Romero Y. Armstrong D. et al. (2013) Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. Inflamm Bowel Dis 19: 332–341.
83. Schoepfer A. Beglinger C. Straumann A. Trummler M. Vavricka S. Bruegger L. et al. (2010) Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 105: 162–169.
84. Schoepfer A. Trummler M. Seeholzer P. Criblez D. Seibold F. (2007) Accuracy of four fecal assays in the diagnosis of colitis. Dis Colon Rectum 50: 1697–1706.
85. Schoepfer A. Trummler M. Seeholzer P. Seibold-Schmid B. Seibold F. (2008) Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis 14: 32–39.
86. Schroeder O. Naumann M. Shastri Y. Povse N. Stein J. (2007) Prospective evaluation of faecal neutrophil-derived proteins in identifying intestinal inflammation: combination of parameters does not improve diagnostic accuracy of calprotectin. Aliment Pharmacol Ther 26: 1035–1042.
87. Shaoul R. Sladek M. Turner D. Paeregaard A. Veres G. Wauters G. et al. ESPGHAN Porto IBD Group. (2012) Limitations of fecal calprotectin at diagnosis in untreated pediatric Crohn's disease. Inflamm Bowel Dis 18: 1493–1497.
88. Sidhu R. Wilson P. Wright A. Yau C. D'Cruz F. Foye L. et al. (2010) Faecal lactoferrin – a novel test to differentiate between the irritable and inflamed bowel? Aliment Pharmacol Ther 31: 1365–1370.
89. Sidler M. Leach S. Day A. (2008) Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children. Inflamm Bowel Dis 14: 359–366.
90. Silberer H. Küppers B. Mickisch O. Baniewicz W. Drescher M. Traber L. et al. (2005) Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome. Clin Lab 51: 117–126.
91. Sipponen T. Kärkkäinen P. Savilahti E. Kolho K. Nuutinen H. Turunen U. et al. (2008) Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Aliment Pharmacol Ther 28: 1221–1229.
92. Sipponen T. Kolho K. (2010) Faecal calprotectin in children with clinically quiescent inflammatory bowel disease. Scand J Gastroenterol 45: 872–877.
93. Sipponen T. Savilahti E. Kärkkäinen P. Kolho K. Nuutinen H. Turunen U. et al. (2008) Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. Inflamm Bowel Dis 14: 1392–1398.
94. Sorrentino D. Paviotti A. Terrosu G. Avellini C. Geraci M. Zarifi D. (2010) Low-dose maintenance therapy with infliximab prevents postsurgical recurrence of Crohn's disease. Clin Gastroenterol Hepatol 8: 591–599.
95. Steinbakk M. Naess-Andresen C. Lingaas E. Dale I. Brandtzaeg P. Fagerhol M. (1990) Antimicrobial actions of calcium binding leucozyte L 1 protein, calprotectin. Lancet 336: 763–765.
96. Sydora M. Sydora B. Fedorak R. (2012) Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome. J Crohns Colitis 6: 207–214.
97. Theede K. Kiszka-Kanowitz M. Mertz Nielsen A. Nordgaard-Lassen I. (2014). The correlation between fecal calprotectin, simple clinical colitis activity index and biochemical markers in ulcerative colitis during high-dose steroid treatment. Scand J Gastroenterol 49: 418–423.
98. Thjodleifsson B. Sigthorsson G. Cariglia N. Reynisdottir I. Gudbjartsson D. Kristjansson K. et al. (2003) Subclinical intestinal inflammation: an inherited abnormality in Crohn's disease relatives? Gastroenterology 124: 1728–1737.
99. Thomas P. Rihani H. Roseth A. Sigthorsson G. Price A. Nicholls R. et al. (2000) Assessment of ileal pouch inflammation by single-stool calprotectin assay. Dis Colon Rectum 43: 214–220.
100. Tibble J. Sigthorsson G. Bridger S. Fagerhol M. Bjarnason I. (2000 a) Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 119: 15–22.
101. Tibble J. Sigthorsson G. Foster R. Forgacs I. Bjarnason I. (2002) Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology 123: 450–460.
102. Tibble J. Teahon K. Thjodleifsson B. Roseth A. Sigthorsson G. Bridger S. et al. (2000 b) A simple method for assessing intestinal inflammation in Crohn's disease. Gut 47: 506–513.
103. Turner D. Leach S. Mack D. Uusoue K. McLernon R. Hyams J. et al. (2010) Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response. Gut 59: 1207–1212.
104. Uchida K. Matsuse R. Tomita S. Sugi K. Saitoh O. Ohshiba S. (1994) Immunochemical detection of human lactoferrin in feces as a new marker for inflammatory gastrointestinal disorders and colon cancer. Clin Biochem 27: 259–264.
105. van de Vijver E. Schreuder A. Cnossen W. Muller Kobold A. van Rheenen P. and the North Netherlands Pediatric IBD Consortium (2012) Safely ruling out inflammatory bowel disease in children and teenagers without referral for endoscopy. Arch Dis Child 97: 1014–1018.
106. van Rheenen P. van de Vijver E. Fidler V. (2010) Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 341: c3369.
107. von Roon A. Karamountzos L. Purkayastha S. Reese G. Darzi A. Teare J. et al. (2007) Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol 102: 803–813.
108. Walker T. Land M. Kartashov A. Saslowsky T. Lyerly D. Boone J. et al. (2007) Fecal lactoferrin is a sensitive and specific marker of disease activity in children and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 44: 414–422.
109. Walkiewicz D. Werlin S. Fish D. Scanlon M. Hanaway P. Kugathasan S. (2008) Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease. Inflamm Bowel Dis 14: 669–673.
110. Wassell J. Wallage M. Brewer E. (2012) Evaluation of the Quantum Blue® rapid test for faecal calprotectin. Ann Clin Biochem 49: 55–58.